vs

Side-by-side financial comparison of BATTALION OIL CORP (BATL) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $31.6M, roughly 1.1× BATTALION OIL CORP). BATTALION OIL CORP runs the higher net margin — 5.7% vs -304.2%, a 309.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -36.1%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -20.1%).

Battalion Oil Corp is an independent energy company engaged in the exploration, development, and production of crude oil, natural gas, and natural gas liquids. It primarily operates assets in the Eagle Ford Shale region of South Texas, serving commercial and industrial clients across North American energy markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BATL vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$31.6M
BATL
Growing faster (revenue YoY)
RXRX
RXRX
+717.9% gap
RXRX
681.7%
-36.1%
BATL
Higher net margin
BATL
BATL
309.9% more per $
BATL
5.7%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-20.1%
BATL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BATL
BATL
RXRX
RXRX
Revenue
$31.6M
$35.5M
Net Profit
$1.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
-33.8%
-304.8%
Net Margin
5.7%
-304.2%
Revenue YoY
-36.1%
681.7%
Net Profit YoY
108.1%
39.6%
EPS (diluted)
$-0.77
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BATL
BATL
RXRX
RXRX
Q4 25
$31.6M
$35.5M
Q3 25
$43.4M
$5.2M
Q2 25
$42.6M
$19.2M
Q1 25
$47.4M
$14.7M
Q4 24
$49.5M
$4.5M
Q3 24
$45.1M
$26.1M
Q2 24
$49.1M
$14.4M
Q1 24
$49.5M
$13.8M
Net Profit
BATL
BATL
RXRX
RXRX
Q4 25
$1.8M
$-108.1M
Q3 25
$-735.0K
$-162.3M
Q2 25
$4.8M
$-171.9M
Q1 25
$6.0M
$-202.5M
Q4 24
$-22.2M
$-178.9M
Q3 24
$21.6M
$-95.8M
Q2 24
$-105.0K
$-97.5M
Q1 24
$-31.2M
$-91.4M
Gross Margin
BATL
BATL
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BATL
BATL
RXRX
RXRX
Q4 25
-33.8%
-304.8%
Q3 25
1.9%
-3327.6%
Q2 25
-0.4%
-916.8%
Q1 25
7.2%
-1297.9%
Q4 24
-36.2%
-4042.4%
Q3 24
2.3%
-377.1%
Q2 24
10.4%
-697.4%
Q1 24
0.0%
-698.4%
Net Margin
BATL
BATL
RXRX
RXRX
Q4 25
5.7%
-304.2%
Q3 25
-1.7%
-3135.3%
Q2 25
11.3%
-894.2%
Q1 25
12.7%
-1373.3%
Q4 24
-44.9%
-3935.5%
Q3 24
48.0%
-367.5%
Q2 24
-0.2%
-676.6%
Q1 24
-63.0%
-662.4%
EPS (diluted)
BATL
BATL
RXRX
RXRX
Q4 25
$-0.77
$-0.17
Q3 25
$-0.91
$-0.36
Q2 25
$-0.21
$-0.41
Q1 25
$-0.35
$-0.50
Q4 24
$-1.47
$-0.56
Q3 24
$0.34
$-0.34
Q2 24
$-0.53
$-0.40
Q1 24
$-2.24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BATL
BATL
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$28.0M
$743.3M
Total DebtLower is stronger
$208.1M
$9.6M
Stockholders' EquityBook value
$-32.8M
$1.1B
Total Assets
$460.7M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BATL
BATL
RXRX
RXRX
Q4 25
$28.0M
$743.3M
Q3 25
$50.5M
$659.8M
Q2 25
$44.6M
$525.1M
Q1 25
$73.6M
$500.5M
Q4 24
$19.7M
$594.4M
Q3 24
$29.8M
$427.6M
Q2 24
$54.4M
$474.3M
Q1 24
$48.9M
$296.3M
Total Debt
BATL
BATL
RXRX
RXRX
Q4 25
$208.1M
$9.6M
Q3 25
$213.8M
$11.9M
Q2 25
$219.4M
$14.2M
Q1 25
$225.1M
$16.4M
Q4 24
$162.1M
$19.0M
Q3 24
$147.8M
$20.5M
Q2 24
$160.4M
$22.9M
Q1 24
$190.2M
Stockholders' Equity
BATL
BATL
RXRX
RXRX
Q4 25
$-32.8M
$1.1B
Q3 25
$-20.3M
$1.0B
Q2 25
$-5.2M
$919.1M
Q1 25
$-1.8M
$933.9M
Q4 24
$4.1M
$1.0B
Q3 24
$35.0M
$524.6M
Q2 24
$22.7M
$584.4M
Q1 24
$31.3M
$401.2M
Total Assets
BATL
BATL
RXRX
RXRX
Q4 25
$460.7M
$1.5B
Q3 25
$491.7M
$1.4B
Q2 25
$498.8M
$1.3B
Q1 25
$506.2M
$1.3B
Q4 24
$431.0M
$1.4B
Q3 24
$458.0M
$726.5M
Q2 24
$487.3M
$775.9M
Q1 24
$488.6M
$557.8M
Debt / Equity
BATL
BATL
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
39.35×
0.02×
Q3 24
4.23×
0.04×
Q2 24
7.07×
0.04×
Q1 24
6.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BATL
BATL
RXRX
RXRX
Operating Cash FlowLast quarter
$-11.8M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
-6.58×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BATL
BATL
RXRX
RXRX
Q4 25
$-11.8M
$-46.1M
Q3 25
$28.0M
$-117.4M
Q2 25
$10.2M
$-76.4M
Q1 25
$12.7M
$-132.0M
Q4 24
$6.7M
$-115.4M
Q3 24
$-5.1M
$-59.2M
Q2 24
$29.8M
$-82.2M
Q1 24
$3.9M
$-102.3M
Free Cash Flow
BATL
BATL
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
BATL
BATL
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
BATL
BATL
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
BATL
BATL
RXRX
RXRX
Q4 25
-6.58×
Q3 25
Q2 25
2.13×
Q1 25
2.11×
Q4 24
Q3 24
-0.23×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BATL
BATL

Oil$28.6M91%
Natural Gas Liquids Reserves$3.9M12%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons